Both metabolic and vascular factors have been invoked in the pathogenesis of diabetic neuropathy but their interrelationships are poorly understood. Both aldose reductase inhibitors and vasodilators improve nerve conduction velocity, nerve blood flow, and (Na+, K+)-ATPase activity in the streptozotocin diabetic rat, implying a metabolic-vascular interaction. Nitric oxide may be the 'bridge' linking these divergent hypotheses of diabetic neuropathy. We propose a model for the pathogenesis of neuropathy invoking metabolic defects both at a vascular and neurochemical level. Early after the induction of experimental diabetes, metabolic defects may lead to a decrease in synthesis of nitric oxide in either the vascular endothelium or the sympathetic ganglia leading to decreased nerve blood flow. In addition, nitric oxide may be involved in more distal defects of somatic nerve metabolism which impair the activity of the nerve NaiK-ATPase by a mechanism involving phosphoinositide signaling and diacyl glycerol and may therefore affect nerve conduction velocity independently of ischaemia. Improved understanding of the effects of hyperglycaemia on nitric oxide metabolism, may provide important clues elucidating the mechanisms underlying the pathogenesis of diabetic neuropathy.
The aetiology of diabetic neuropathy remains unknown but evidence implicates a multifactorial pathogenesis.
The potential mechanisms leading to its development are difficult to elucidate in many diabetic patients due to the pathological changes typically being well advanced and thus obscuring the early manifestations which offer aetiological clues. Most data therefore have been acquired from the diabetic rat model which develops similar functional and structural nerve defects to man. Two approaches have been utilized to explore the pathogenesis of neuropathy. Firstly, the diabetic rat has been used to characterize the metabolic and physiological defects leading to the development of experimental neuropathy and, secondly, use has been made of selective therapeutic interventions to reverse the hyperglycemia-induced abnormalities.
Numerous interventions have been shown to prevent or ameliorate nerve conduction slowing and nerve metabolic and blood flow abnormalities in the diabetic rat model. Given the diverse nature of these therapeutic interventions, can a unified hypothesis be created?
Considerable evidence implicates nerve ischaemia in the pathogenesis of diabetic nerve conduction slowing as haemodynamic and oximetric measurements in anaesthetized rats have demonstrated reduced endoneurial blood flow and oxygen tension, and increased endoneurial vascular resistance early after the induction of streptozotocin diabetes.' Studies from the same laboratory have also demonstrated that in streptozotocin diabetic rats endoneurial blood flow and nerve conduction can be partially or completely corrected by a variety of vasodilatory agents including the ACE inhibitor lisinopril.2 Moreover, many metabolic interventions which have been demonstrated to prevent the development of nerve conduction slowing in diabetic rats may also be working through a vascular mechanism. For example, aldose reductase inhibitors (ARls) have been shown to correct the early reduction in nerve blood flow in experimental diabetes-' and also restore to normal the diabetes or hyperglycaemia-induced deficits in endothelium-dependent vascular r e l a~a t i o n .~ Although the success of vasodi latory therapeutic interventions on the reversal or prevention of nerve conduction slowing has confirmed the importance of blood flow deficits in the pathogenesis of experimental neuropathy, a number of questions remain. For example, how does diabetes precipitate a decrease in endoneurial blood flow? How does this decreased blood flow cause nerve conduction slowing? Can therapeutic interventions which fail to correct blood flow ameliorate or prevent experimental neuropathy?
We propose a model for the pathogenesis of neuropathy invoking metabolic defects both at a vascular and neurochemical level (Figure 1 ). These defects may mediate both the early reduction in nerve blood flow For example, soon after the induction of diabetes in the rat, metabolic defects in either the vascular endothelium or within the sympathetic ganglia could precipitate an increase in basal vascular tone leading to the development of nerve ischaemia. In addition, more distal defects of somatic nerve metabolism could directly effect nerve conduction velocity independently of nerve ischaemia potentially by impairing the activity of the nerve NaiKATPase by a mechanism involving diacyl glycerol (DAG). Traditionally, the principal site of metabolic defects involving phosphoinositide metabolism has been the peripheral nerve trunks. It is also possible that these defects could occur in other sites such as the autonomic nervous system and lead to secondary disturbances of vascular f u n~t i o n .~ This situation is however complex as glucose may have bidirectional effects on diacylglycerol (DAG) and protein kinase C (PKC) activity. Diabetes and/or hyperglycaemia have been reported to decrease DAG and PKC activity in some tissues including peripheral nerve6,' while in others such as the vascular endothelium hyperglycaemia appears to increase total DAG and PKC activity.s Our studies in human retinal pigment epithelial (RPE) cells suggest that the determining factor for the direction of DAG changes is aldose reductase activity and also the extent to which myoinositol depletion occurs.9 RPE cells with high basal aldose reductase expression demonstrate glucose-induced decrease in myo-inositol and PKC, contrasting with PKC activation in cells with low basal aldose reductase expression. How could changes in tissue polyol pathway flux and PKC alter nerve blood flow? We propose that the bridge between these metabolic perturbations and nerve blood flow is nitric oxide. Nitric oxide (NO) is a highly reactive,
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short-lived radical with a broad spectrum of metabolic functions. It has been identified as a prime candidate for the endothelium-derived relaxing factor mediating vasodilatation, it mediates macrophage cytotoxicity, and plays an important role as a neuronal messenger within the CNS and may function as an inhibitory neurotransmitter,lO."
In order to see whether the beneficial effects of aldose reductase inhibitors on nerve conduction velocity involve a nitric oxide-mediated mechanism, we evaluated whether inhibition of nitric oxide synthase (NOS) with N-nitro-L-arginine methyl ester (L-NAME) could block the effects of an ARI on nerve conduction. Our studies in streptozotocin diabetes rats'2 demonstrated that L-NAME could reverse the protective effects of the ARI sorbinil on nerve conduction slowing in diabetic rats, a finding which supported the role of N O in the maintenance of normal nerve function. Increased glucose flux through the polyol pathway may therefore be a proximal metabolic defect in our model of neuropathy, in that its detrimental effects on nerve conduction velocity may be principally mediated by a reduction in nerve blood flow.
However, is there evidence for a distal metabolic component that could explain nerve conduction slowing independently of nerve ischaemia? Can distal therapeutic intervention correct nerve dysfunction independently of nerve blood flow or N O ? Our data in diabetic rats suggest that this is the case.12 For example, the beneficial effects of myo-inositol on nerve conduction slowing are thought to be mediated by correction of the nerve Na/ K-ATPase.' ',I4 Our studies have shown that the protective effects of myo-inositol (MI) supplementation on nerve conduction velocity are not blocked by NOS inhibitors.12 Therefore as L-NAME appears to block the beneficial effects of an ARI, but not M I supplementation, and MI D m is not thought to mediate nerve blood flow, metabolic intervention aimed at correcting distal defects in nerve metabolism can correct nerve conduction slowing independently of blood flow.
Although the effects of NO in the preservation of nerve function are thought to be primarily mediated by a vascular mechanism, some data support a more distal metabolic role. For example, the reproduction of the glucose-induced decrease in rabbit aortic NaiK-ATPase by an NOS i n h i b i t~r '~ supports the concept that N O can directly regulate Na/K-ATPase activity. Moreover, our studies have demonstrated that diabetic nerve Na/ K-ATPase activity can be reproduced in nondiabetic rats given L-NAME for 3 months.12 Therefore N O could be modulating nerve function at both a proximal vascular level, and a more distal metabolic site.
However, how does the polyol pathway and hyperglycaemia alter N O metabolism? In mammalian CNS and endothelial cells, N O is generated by the enzymatic conversion of L-arginine to citrulline by NO-synthase which in these tissues is a calcium-calmodulin-dependent constitutive isoform ( C N O S ) . '~, '~, '~ This cNOS generates low levels of N O which in vascular tissue modulates basal vascular tone by interacting with and activating heme-containing soluble guanylate cyclase in smooth muscle generating cGMP. In macrophages and smooth muscle, however, considerably higher levels of N O are also produced via a calcium-calmodulin-independent cytokine-inducible isoform (iNOS) which may promote cytokine-mediated cytotoxicity.
Glucose-induced alterations in PKC activity are proposed to modulate the activity of cNOS by direct phosphorylation. ' 6 , 1 Controversy however surrounds the relationship between PKC and nitric oxide synthase. For example, PKC activation has been reported to both stimulate cNOS activity18 and also to decrease cNOS a~t i v i t y . '~, '~ We propose that flux through the polyol pathway could deleteriously affect N O synthesis by two mechanisms. Firstly, we have proposed that as aldose reductase and NOS share NADPH as an obligate cofactor, enhanced flux through the polyol pathway could consume NADPH thereby limiting its availability for the synthesis of N0.5,'2 A second possibility is that decreased PKC activity in diabetes may reduce nitric oxide synthesis. Therefore accumulating evidence links N O depletion to nerve conduction slowing in diabetes. However, at what tissue site could these derangements be occurring?
Although local vascular NO depletion may directly contribute to nerve ischaemia, the potential of NO as an inhibitory neurotransmitter and its role in the maintenance of blood pressure via modulating sympathetic tone suggest another potential mechanism. The acute reduction in nerve blood flow in diabetes may be mediated by increased sympathetic tone, as adrenergic sympathectomy restores both nerve blood flow and nerve conduction to normal levels in acute experimental diabetes.' If NO is functioning as an inhibitory neurotransmitter, it is tempting to speculate that post-synaptic 2 94 neuronal N O might dampen presynaptic acetylcholine release thereby modulating peripheral sympathetic tone.
In summary, therefore, NO may be the 'bridge' linking the metabolic and vascular hypotheses of diabetic neuropathy. Early after the induction of diabetes, metabolic defects may ledd to a decrease in synthesis of N O in either the vascular endothelium or the sympathetic ganglia leading to decreased nerve blood flow. In addition, N O may be involved in more distal defects of somatic nerve metabolism which impair the activity of the nerve NaiK-ATPase and may therefore affect nerve conduction velocity independently of ischaemia. Improved understanding of the effects of hyperglycemia on N O metabolism, may provide important clues elucidating the mechanisms underlying the pathogenesis of diabetic neuropathy.
